Cargando…
Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical Setting
PURPOSE: To evaluate the frequency and clinical impact of switches in antiplatelet therapy following implementation of CYP2C19 genotyping after percutaneous coronary intervention (PCI). METHODS: The frequency of escalation (clopidogrel switched to prasugrel/ticagrelor) and de-escalation (prasugrel/t...
Autores principales: | Martin, Jesse, Williams, Alexis K., Klein, Melissa D., Sriramoju, Vindhya B., Madan, Shivanshu, Rossi, Joseph S., Clarke, Megan, Cicci, Jonathan D., Cavallari, Larisa H., Weck, Karen E., Stouffer, George A., Lee, Craig R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946839/ https://www.ncbi.nlm.nih.gov/pubmed/31316169 http://dx.doi.org/10.1038/s41436-019-0611-1 |
Ejemplares similares
-
Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
por: Nguyen, Anh B., et al.
Publicado: (2022) -
Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
por: Lee, Sang Yeub, et al.
Publicado: (2023) -
Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
por: Gower, Megan N, et al.
Publicado: (2020) -
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice
por: Gragnano, Felice, et al.
Publicado: (2022) -
Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)